Evidence map›Paper›PMID 33739371›Full record

ReviewCardiovascular research2022

Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia.

Alexandre Persu, Piotr Dobrowolski, Heather L Gornik, Jeffrey W Olin, David Adlam, Michel Azizi, Pierre Boutouyrie, Rosa Maria Bruno, Marion Boulanger, Jean-Baptiste Demoulin and 15 more

Open access · greenAbstract readReview
In one paragraph

Review in Cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Characteristics of Asian patients with Fibromuscular Dysplasia: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cerebrovascular fibromuscular dysplasia.Therapeutic advances in neurological disorders · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Cerebrovascular Fibromuscular Dysplasia - A Practical Review.Vascular health and risk management · 2023
    Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 14 institutions in 8 countries.

Alexandre PersuPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.ORCID 0000-0002-4007-9695
Piotr DobrowolskiPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.ORCID 0000-0002-8919-1661
Heather L GornikDepartment of Hypertension, National Institute of Cardiology, Warsaw, Poland.ORCID 0000-0002-5849-4010
Jeffrey W OlinUniversity Hospitals Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-3374-616X
David AdlamZena and Michael A. Wiener Cardiovascular Institute and Marie-José and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0080-9884
Michel AziziDepartment of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester University, Leicester, UK.
Pierre BoutouyrieHypertension Department and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
Rosa Maria BrunoHypertension Department and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.ORCID 0000-0002-6107-3356
Marion BoulangerPharmacology Department and DMU CARTE, AP-HP, Hôpital Européen Georges-Pompidou, Paris, France.
Jean-Baptiste DemoulinUniversité Catholique de Louvain, de Duve Institute, Brussels, Belgium.ORCID 0000-0002-8016-6689
Santhi K GaneshDivision of Cardiovascular Medicine, Department of Internal Medicine, and Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-3663-5249
Tomasz J GuzikJagiellonian University, Collegium Medicum, Krakow, Poland.
Magdalena JanuszewiczDepartment of Hypertension, National Institute of Cardiology, Warsaw, Poland.ORCID 0000-0002-4725-3545
Jason C KovacicUniversity Hospitals Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-4555-769X
Mariusz KrukDepartment of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland.
Peter de LeeuwDepartment of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-4949-5812
Bart L LoeysCenter for Medical Genetics, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.ORCID 0000-0003-3703-9518
Marco PappaccogliPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.ORCID 0000-0003-4107-8122
Melanie H A M PerikCenter for Medical Genetics, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-2453-5662
Emmanuel TouzéNormandie Université, UNICAEN, Inserm U1237, CHU Caen Normandie, Caen, France.
Patricia Van der NiepenDepartment of Nephrology & Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.ORCID 0000-0002-6401-1580
Daan J L Van TwistZuyderland Medical Centre, Sittard/Heerlen, The Netherlands.
Ewa Warchoł-CelińskaPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Aleksander PrejbiszPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.ORCID 0000-0001-7085-0244
Andrzej JanuszewiczPole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique and Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Cliniques Universitaires Saint-Luc · BEInserm · FRInstitute of Cardiology · PLUniversity of Antwerp · BECardiovascular Institute of the South · USde Duve Institute · BEJagiellonian University · PLMaastricht University · NLMedical University of Warsaw · PLUniversity Hospitals of Cleveland · USUniversity of Michigan · USVictor Chang Cardiac Research Institute · AUVrije Universiteit Brussel · BEZuyderland Medisch Centrum · NL

Funding

Genome-Wide Association Analysis in Essential Hypertension (FEHGAS study)R01HL086694 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARAVINDA CHAKRAVARTI · 2007 to 2026
$21.2M
Genetic Studies of The Impact of Hematologic Traits On Cardiovascular DiseaseR01HL122684 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GANESH, SANTHI K · 2015 to 2019
$3.4M
Therapeutic Mechanisms of Cardiac Progenitors in Ischemic CardiomyopathyR01HL135093 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FISH, KENNETH MICHAEL, KOVACIC, JASON CIRIL · 2017 to 2020
$3.4M
Genetic and Genomic Analysis of Arterial DysplasiaR01HL139672 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GANESH, SANTHI K · 2018 to 2021
$2.9M
Understanding the Molecular Mechanisms of Fibromuscular DysplasiaR01HL148167 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KADIAN-DODOV, DANIELLA, KOVACIC, JASON CIRIL · 2020 to 2023
$2.8M
Toward Therapeutic Manipulation of Endothelial to Mesenchymal TransitionR01HL130423 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ISHIKAWA, KIYOTAKE, KOVACIC, JASON CIRIL · 2016 to 2020
$2.1M
Department of HealthNHLBI NIH HHS R01 HL086694NHLBI NIH HHS R01 HL122684NHLBI NIH HHS R01 HL130423NHLBI NIH HHS R01 HL135093NHLBI NIH HHS R01 HL139672NHLBI NIH HHS R01 HL148167
6 · The paper itself

Abstract

Fibromuscular dysplasia (FMD) is a non-atherosclerotic vascular disease that may involve medium-sized muscular arteries throughout the body. The majority of FMD patients are women. Although a variety of genetic, mechanical, and hormonal factors play a role in the pathogenesis of FMD, overall, its cause remains poorly understood. It is probable that the pathogenesis of FMD is linked to a combination of genetic and environmental factors. Extensive studies have correlated the arterial lesions of FMD to histopathological findings of arterial fibrosis, cellular hyperplasia, and distortion of the abnormal architecture of the arterial wall. More recently, the vascular phenotype of lesions associated with FMD has been expanded to include arterial aneurysms, dissections, and tortuosity. However, in the absence of a string-of-beads or focal stenosis, these lesions do not suffice to establish the diagnosis. While FMD most commonly involves renal and cerebrovascular arteries, involvement of most arteries throughout the body has been reported. Increasing evidence highlights that FMD is a systemic arterial disease and that subclinical alterations can be found in non-affected arterial segments. Recent significant progress in FMD-related research has led to improve our understanding of the disease's clinical manifestations, natural history, epidemiology, and genetics. Ongoing work continues to focus on FMD genetics and proteomics, physiological effects of FMD on cardiovascular structure and function, and novel imaging modalities and blood-based biomarkers that can be used to identify subclinical FMD. It is also hoped that the next decade will bring the development of multi-centred and potentially international clinical trials to provide comparative effectiveness data to inform the optimal management of patients with FMD.

Indexed as

ArteriesFibromuscular DysplasiaAnimalsBiomedical ResearchGene Expression ProfilingGenetic Predisposition to DiseaseHemodynamicsHumansMolecular Diagnostic TechniquesPhenotypePredictive Value of TestsPrognosisProteomicsRisk AssessmentRisk FactorsVascular RemodelingFibromuscular dysplasiaGenomicProteomicResearchSpontaneous dissection

Identifiers

PMID33739371
PMCPMC8752362
OpenAlexW3136726630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.